A study presented at the 50th International Liver Congress in Vienna, Austria reports that long-term use of entecavir (ETV) or tenofovir (TDF) resulted in excellent five-year survival for patients with chronic hepatitis B virus (CHB) infection.
In this multi-center, large-scale ongoing cohort study, researchers assessed survival rates in 1,815 Caucasian CHB patients with or without compensated cirrhosis and no hepatocellular carcinoma (HCC) at baseline who had received either ETV or TDF for at least 12 months. The five-year overall survival rate was 95% in the total patient population, although it was significantly greater in non-cirrhotic patients (97%) vs. cirrhotic patients (92%). The five-year survival rate was 97.5% when only liver-related deaths or liver transplantation were included.
The results also indicated that better overall survival was independently associated with the absence of HCC, but not with cirrhosis or gender. Liver-related survival was associated only with the absence of HCC. The researchers concluded that because the development of HCC appears to play an important role in mortality, clinicians should consider these findings when managing patients with CHB.
For more information visit EASL.eu.